JP2016533753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016533753A5 JP2016533753A5 JP2016537898A JP2016537898A JP2016533753A5 JP 2016533753 A5 JP2016533753 A5 JP 2016533753A5 JP 2016537898 A JP2016537898 A JP 2016537898A JP 2016537898 A JP2016537898 A JP 2016537898A JP 2016533753 A5 JP2016533753 A5 JP 2016533753A5
- Authority
- JP
- Japan
- Prior art keywords
- kynureninase
- present
- therapy
- seq
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010031676 Kynureninase Proteins 0.000 claims description 45
- 102000005447 kynureninase Human genes 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 15
- 238000011319 anticancer therapy Methods 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 101001021858 Homo sapiens Kynureninase Proteins 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 241000288906 Primates Species 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 238000001794 hormone therapy Methods 0.000 claims description 5
- 238000009169 immunotherapy Methods 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 102220487216 Cytochrome b-245 chaperone 1_F306L_mutation Human genes 0.000 claims description 3
- 238000000315 cryotherapy Methods 0.000 claims description 3
- 238000001361 intraarterial administration Methods 0.000 claims description 3
- 238000007917 intracranial administration Methods 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 230000002601 intratumoral effect Effects 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 210000004027 cell Anatomy 0.000 description 17
- 108020004707 nucleic acids Proteins 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 230000009261 transgenic effect Effects 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 2
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 description 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 2
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 description 2
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 2
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001021851 Pseudomonas fluorescens Kynureninase Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361872132P | 2013-08-30 | 2013-08-30 | |
| US61/872,132 | 2013-08-30 | ||
| US201461986366P | 2014-04-30 | 2014-04-30 | |
| US61/986,366 | 2014-04-30 | ||
| PCT/US2014/053437 WO2015031771A2 (en) | 2013-08-30 | 2014-08-29 | Administration of kynurenine depleting enzymes for tumor therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018042760A Division JP7029316B2 (ja) | 2013-08-30 | 2018-03-09 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533753A JP2016533753A (ja) | 2016-11-04 |
| JP2016533753A5 true JP2016533753A5 (enExample) | 2017-10-05 |
| JP6307163B2 JP6307163B2 (ja) | 2018-04-04 |
Family
ID=52583559
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537898A Active JP6307163B2 (ja) | 2013-08-30 | 2014-08-29 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| JP2018042760A Active JP7029316B2 (ja) | 2013-08-30 | 2018-03-09 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| JP2020073212A Withdrawn JP2020111611A (ja) | 2013-08-30 | 2020-04-16 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| JP2022132161A Pending JP2022159570A (ja) | 2013-08-30 | 2022-08-23 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018042760A Active JP7029316B2 (ja) | 2013-08-30 | 2018-03-09 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| JP2020073212A Withdrawn JP2020111611A (ja) | 2013-08-30 | 2020-04-16 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| JP2022132161A Pending JP2022159570A (ja) | 2013-08-30 | 2022-08-23 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9808486B2 (enExample) |
| EP (2) | EP3492094A1 (enExample) |
| JP (4) | JP6307163B2 (enExample) |
| KR (2) | KR102271498B1 (enExample) |
| CN (2) | CN105722522B (enExample) |
| AU (1) | AU2014312119B2 (enExample) |
| BR (1) | BR112016004095A2 (enExample) |
| CA (2) | CA2922670C (enExample) |
| ES (1) | ES2707711T3 (enExample) |
| IL (2) | IL244312B (enExample) |
| WO (1) | WO2015031771A2 (enExample) |
| ZA (1) | ZA201601443B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP3492094A1 (en) | 2013-08-30 | 2019-06-05 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| EP3186371B1 (en) * | 2014-08-29 | 2024-08-14 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| EP3207130B1 (en) | 2014-10-14 | 2019-08-07 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| CA2984624A1 (en) * | 2015-03-18 | 2016-09-22 | Baylor College Of Medicine | Her2/erbb2 chimeric antigen receptor |
| US11723932B2 (en) | 2016-01-11 | 2023-08-15 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| WO2017151860A1 (en) | 2016-03-02 | 2017-09-08 | Broard Of Regents, The University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| KR20190084053A (ko) | 2016-10-13 | 2019-07-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | 트립토판 대사 경로 조절인자 관련 면역 치료 방법 및 조성물 |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| EP3651782A1 (en) * | 2017-07-12 | 2020-05-20 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| WO2019089740A1 (en) * | 2017-11-03 | 2019-05-09 | Dana-Farber Cancer Institute, Inc. | Biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy |
| AU2019209432A1 (en) | 2018-01-22 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| CN111936518A (zh) | 2018-02-06 | 2020-11-13 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| JP7432851B2 (ja) * | 2018-04-16 | 2024-02-19 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ヒトキヌレニナーゼ酵素及びその使用 |
| CN110412179A (zh) * | 2018-04-26 | 2019-11-05 | 缪荣明 | 一种液相色谱检测颗粒酶a的方法 |
| US20220056407A1 (en) * | 2018-12-14 | 2022-02-24 | Autolus Limited | Cell |
| WO2021076966A1 (en) * | 2019-10-17 | 2021-04-22 | Ikena Oncology, Inc. | Pegylated kynureninase enzymes and uses thereof for the treatment of cancer |
| JPWO2023229024A1 (enExample) * | 2022-05-27 | 2023-11-30 | ||
| WO2024085280A1 (ko) * | 2022-10-20 | 2024-04-25 | 서울대학교 산학협력단 | 신규한 키뉴레니나제 및 이의 용도 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US20030194721A1 (en) | 2001-09-19 | 2003-10-16 | Incyte Genomics, Inc. | Genes expressed in treated foam cells |
| EP1470240A4 (en) | 2002-02-01 | 2006-08-30 | Millennium Pharm Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES USING 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419 , 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2 |
| CN1330774C (zh) * | 2002-03-01 | 2007-08-08 | 国家人类基因组南方研究中心 | 犬尿氨酸水解酶多态性及其用途 |
| CA2520586C (en) | 2003-03-27 | 2011-06-14 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use |
| US20070207158A1 (en) | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| JP2008237022A (ja) | 2005-06-30 | 2008-10-09 | Osaka Prefecture | 非小細胞肺がんの予防・治療剤および診断薬 |
| JP5319532B2 (ja) * | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル |
| GB0625310D0 (en) * | 2006-12-19 | 2007-01-24 | Bioalvo | Yeast platform construction and screening methods |
| EP2483301A1 (en) | 2009-10-01 | 2012-08-08 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US9212229B2 (en) | 2010-09-08 | 2015-12-15 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012099441A2 (ko) | 2011-01-21 | 2012-07-26 | 인제대학교산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| KR20120085209A (ko) * | 2011-01-21 | 2012-07-31 | 인제대학교 산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| US9593062B2 (en) * | 2011-09-07 | 2017-03-14 | Deutschland Krebsforschungszentrum | Means and methods for treating and/or preventing natural AHR ligand-dependent cancer |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| EP3492094A1 (en) | 2013-08-30 | 2019-06-05 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| EP3186371B1 (en) | 2014-08-29 | 2024-08-14 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| WO2017151860A1 (en) | 2016-03-02 | 2017-09-08 | Broard Of Regents, The University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| JP6912171B2 (ja) * | 2016-09-15 | 2021-07-28 | 株式会社トプコン | 眼科検査装置 |
| JP7432851B2 (ja) | 2018-04-16 | 2024-02-19 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ヒトキヌレニナーゼ酵素及びその使用 |
-
2014
- 2014-08-29 EP EP18204264.8A patent/EP3492094A1/en active Pending
- 2014-08-29 EP EP14840339.7A patent/EP3038636B1/en active Active
- 2014-08-29 BR BR112016004095A patent/BR112016004095A2/pt not_active Application Discontinuation
- 2014-08-29 AU AU2014312119A patent/AU2014312119B2/en active Active
- 2014-08-29 JP JP2016537898A patent/JP6307163B2/ja active Active
- 2014-08-29 CN CN201480053899.1A patent/CN105722522B/zh active Active
- 2014-08-29 WO PCT/US2014/053437 patent/WO2015031771A2/en not_active Ceased
- 2014-08-29 ES ES14840339T patent/ES2707711T3/es active Active
- 2014-08-29 CA CA2922670A patent/CA2922670C/en active Active
- 2014-08-29 CA CA3173052A patent/CA3173052A1/en active Pending
- 2014-08-29 KR KR1020167008486A patent/KR102271498B1/ko active Active
- 2014-08-29 CN CN202111132607.1A patent/CN113957061A/zh active Pending
- 2014-08-29 US US14/473,040 patent/US9808486B2/en active Active
- 2014-08-29 KR KR1020217019661A patent/KR102442231B1/ko active Active
-
2016
- 2016-02-28 IL IL244312A patent/IL244312B/en active IP Right Grant
- 2016-03-02 ZA ZA2016/01443A patent/ZA201601443B/en unknown
- 2016-11-14 US US15/351,060 patent/US20170056449A1/en not_active Abandoned
-
2018
- 2018-03-09 JP JP2018042760A patent/JP7029316B2/ja active Active
-
2019
- 2019-02-19 IL IL264901A patent/IL264901B/en active IP Right Grant
- 2019-04-02 US US16/373,588 patent/US10772913B2/en active Active
-
2020
- 2020-04-16 JP JP2020073212A patent/JP2020111611A/ja not_active Withdrawn
- 2020-08-18 US US16/996,806 patent/US11534463B2/en active Active
-
2022
- 2022-08-23 JP JP2022132161A patent/JP2022159570A/ja active Pending
- 2022-12-13 US US18/065,451 patent/US20240091258A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016533753A5 (enExample) | ||
| TWI669311B (zh) | Ｉｌ－１５異源二聚體蛋白及其用途 | |
| Dasgupta et al. | Inhibition of NK cell activity through TGF-β1 by down-regulation of NKG2D in a murine model of head and neck cancer | |
| Gildener-Leapman et al. | Promising systemic immunotherapies in head and neck squamous cell carcinoma | |
| JP6731405B2 (ja) | ウイルス粒子を用いた癌免疫療法 | |
| JP2018505893A5 (enExample) | ||
| CN110835371A (zh) | 抗ccr8单克隆抗体及其应用 | |
| JP2019507582A5 (enExample) | ||
| US8597647B1 (en) | Humanized anti-IL-20 antibody and uses thereof | |
| JP7099956B2 (ja) | がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種 | |
| JP2017526368A5 (enExample) | ||
| JP2021521777A (ja) | ヒトキヌレニナーゼ酵素及びその使用 | |
| CN112955168A (zh) | 与另一种药理活性剂组合的长效白介素-15受体激动剂 | |
| Liu et al. | Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody–interleukin-2 fusion proteins | |
| CN109929037B (zh) | 针对程序性死亡配体的结合物及其应用 | |
| Namkoong et al. | Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11 | |
| EP4471068A1 (en) | Bifunctional molecule formed by fusion of pd1 antibody and interleukin 2 | |
| JP2021506320A5 (enExample) | ||
| US20230406927A1 (en) | Masked single-domain antibodies and methods thereof | |
| CN101210048A (zh) | 用于靶向结合髓系白血病细胞的抗cd33的工程抗体及其表达载体和用途 | |
| US20240115675A1 (en) | Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine | |
| EP4168431A1 (en) | Modified cxcl10 for immunotherapy of cancer diseases | |
| WO2008037225A1 (es) | Composiciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico | |
| KR102666000B1 (ko) | cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물 | |
| CN102372780A (zh) | 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用 |